Posts Tagged: "CAFC"

Response Filed to SCOTUS Petition on Question of Whether Reserve Banks Are ‘Persons’ Eligible to Request PTAB Review

On November 25, the Federal Reserve Bank of Atlanta (Bank of Atlanta) filed a brief in opposition in response to a petition for a writ of certiorari filed by Bozeman Financial LLC (Bozeman) with the U.S. Supreme Court on September 8. Bozeman’s petition followed a decision of the U.S. Court of Appeals for the Federal Circuit (CAFC), which affirmed a decision of the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) holding that the PTAB correctly determined claims 21–24 of U.S. Patent No. 6,754,640 (’640 patent) and claims 1-20 of U.S. Patent 8,768,840 (’840 patent), both owned by Bozeman Financial LLC (Bozeman), to be directed to patent ineligible subject matter under 35 U.S.C. § 101. In reaching the decision, the CAFC first determined the appellees, all 12 of the United States Federal Reserve Banks, were considered “persons” under the America Invents Act (AIA) and, therefore, eligible to petition for post-issuance review under the AIA. In its brief in opposition, the Bank of Atlanta asserted that the CAFC “correctly concluded that the Reserve Banks should not be viewed as part of the sovereign for purposes of the AIA’s post-grant review provisions” and that the Supreme Court’s review is not warranted.

Federal Circuit Affirms Admissibility of Evidence Supporting Availability of Prior Art Submitted in IPR Reply Brief

On November 25, the Federal Circuit affirmed a decision of the Patent Trial and Appeal Board in VidStream LLC v. Twitter, Inc., in which the PTAB held VidStream’s patent claims unpatentable as obvious over the applied prior art. In particular, the CAFC affirmed the PTAB’s holding that Twitter properly established an earlier filing date of a reference based on evidence submitted in a reply brief.

Cybergenetics Appeals Ohio Federal Judge Ruling that Alice Kills DNA Analysis Patents

On October 13, 2020, Cybergenetics filed a notice of appeal to the Federal Circuit from a decision of the Northern District of Ohio, Eastern Division, that held the patent claims asserted by Cybergenetics invalid under 35 U.S.C. 101, and granting the defendant’s Rule 12(b)(6) motion to dismiss.  Cybergenetics’ brief on appeal is due December 28, 2020.

Federal Circuit Affirms $90 Million Verdict Against GSK Inhalers

On November 19, the Federal Circuit issued a precedential decision in Vectura Limited v. GlaxoSmithKline LLC in which the court affirmed a judgment entered against GSK finding that Ellipta-brand inhalers infringed patent claims asserted by Vectura. On appeal, GSK had argued that it was entitled to new trials on infringement and damages, but the Federal Circuit disagreed.

CAFC Issues Modified Opinion on IPR Estoppel Following Panel Rehearing Petition

On November 20, the Federal Circuit issued a modified opinion following a petition for panel rehearing filed by Network-1. The petition came after the CAFC affirmed-in-part and reversed-in-part a district court’s claim construction and remanded the case to the district court on September 24, 2020, in Network-1 Technologies, Inc. v. Hewlett-Packard Company. In the revised opinion, the CAFC said that it would not consider Network-1’s alternative grounds for granting a judgment as a matter of law (JMOL) on validity nor its new trial motion in the first instance.